NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Absci Corporation (ABSI) Stock Analysis

Absci Corporation (ABSI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ABSI

$10.04

+$0.97 (+10.69%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABSI with… →

ABSI Key Statistics

As of Oct 21, 2026
Trading
Open
$9.24
Previous Close
$9.07
Day's Range
9.11–10.20
52-Week Range
2.24–12.06
Volume
5.35M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.28
Valuation
Market Cap
$1.72B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1,103.78
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.79
Financials (FY)
Revenue (FY)
$2.80M−38.24%
Net Income (FY)
−$115.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
171.61M
1-Year Return
+117.79%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
3.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ABSI closed at $10.04, +117.79% over 1 year.

Absci Corporation (ABSI) has a market capitalization of $1.72B.

In fiscal 2025, ABSI reported revenue of $2.80M.

ABSI Stock Return by Calendar Year

Absci Corporation (ABSI) return since Jul 2021: what $10,000 became

1 year
$10,000 $21,779
+117.79%
5 years
$10,000 $8,465
−15.35%
Since Jul 2021
$10,000 $4,650
−53.50%

If you had invested $10,000 in Absci Corporation (ABSI) at the close on July 22, 2021, the earliest close on record here, it would have been worth $4,650 at the close on October 21, 2026: −53.50% in total, −13.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+187.68%
2025+33.21%
2024−37.62%
2023+100.00%
2022−74.39%
2021 (partial year)−62.02%

As of October 21, 2026.

ABSI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.80M−$115.18M−4,113.7%
2024$4.53M−$103.11M−2,274.1%
2023$5.72M−$110.57M−1,933.6%
2022$5.75M−$104.90M−1,825.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.80M—−$125.42M−$115.18M−4,113.7%
2024$4.53M—−$108.89M−$103.11M−2,274.1%
2023$5.72M—−$94.18M−$110.57M−1,933.6%
2022$5.75M—−$106.75M−$104.90M−1,825.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABSI Valuation vs Biotechnology Median

Median of 608 stocks
MetricABSIBiotechnology medianvs median
P/S ratio1,103.7813.3083.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Absci Corporation (ABSI) at $1.72B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 140 employees.

ABSI last closed at $10.04 on October 21, 2026. That is +$0.97 (+10.69%) against the previous close. The 52-week range on file runs from $2.24 to $12.06. The latest close sits 348.21% above that 52-week low.

Financial Health

In fiscal 2025, Absci Corporation reported revenue of $2.80M. That is −38.24% against the prior fiscal year, when revenue was $4.53M. The same year closed with a net loss of $115.18M. Trailing earnings per share are −0.79.

Across the 4 fiscal years on file, revenue moves from $5.75M in 2022 to $2.80M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1,103.78 times revenue. On price-to-sales that is 83 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +117.79%. Measured over 5 years, that is −3.28% a year compounded. Beta against the wider market is reported at 2.28. Annualized volatility over the trailing 5 years is 97.55%.

Growth & Income

No dividend is on file for ABSI.

So far in 2026 the total return is +187.68%. Across the complete calendar years on file, 2023 returned +100.00% and 2022 returned −74.39%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Absci Corporation (ABSI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Absci Corporation ABSI $1.72B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Absci Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Absci Corporation

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Visit website →